exemestane,tamoxifen,triptorelin
azurity pharmaceuticals,astrazeneca,pfizer
['soft trial']
dr. lauren c. brown presents pam50 intrinsic subtype &amp; risk of recurrence scores from the soft trial population #asco23 
Assistant Professor, Breast Surgical Oncology & Assoc. PD, BSO Fellowship @MDAndersonNews. Alum of @UChiPritzker, @uchicagosurgery & @WUSTL. Tweets are my own.